Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05625750
Recruiting Observational

Observational Study About Patients Diagnosed With NAFLD

NCT05625750 · tracked via the Priya Life Science China tracker
Sponsor
Xiangya Hospital of Central South University
Phase
Observational
Started
2022-04-27
Last updated
2022-11-30

Condition(s) studied

Nonalcoholic Fatty Liver Disease

Study summary

Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1\. patients diagnosed with nonalcoholic fatty liver disease Exclusion Criteria: 1. patients suspected of excessive alcohol consumption 2. malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation 3. incomplete data such as HBV serological results and abdominal ultrasound results 4. patients who refuse to sign informed consent

Primary outcome measure(s)

  • BMI — 3 weeks
    BMI stands for body mass index. This is the ratio of a person's height to their weight.
  • alcohol intake — 3 years
    alcohol consumption every week

Trial sites (1)

FacilityCityRegionStatus
Department of Infectious Disease, Xiangya Hospital, Central South University Changsha Hunan Recruiting

More Xiangya Hospital of Central South University trials in China

Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: Recruiting
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST Recruiting
RET-Targeted Molecular Imaging Probes in Prostate Cancer Active, not recruiting
Chinese ET Registry (CETR) Recruiting
Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea Active, not recruiting

Other trials for the same condition

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss Recruiting
Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease Recruiting
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease Recruiting
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD Recruiting
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05625750 on ClinicalTrials.gov ↗ ← All trials in China